Several aspects associated with T2D that contribute to AD and vice versa were investigated in this study. Additionally, this work reveals the role of Ab40, Ab42, insulin, HbA1c, lipid profile disturbance, CRP, D-dimer, and magnesium in the bidirectional association between T2D and the pathogenesis of AD, that is powered by their correlations, and therefore the possibility of utilizing Ab as a biochemical marker of T2D in Alzheimer's patients is recommended. Furthermore, the ameloriating effect of anti-Alzheimer's drugs on diabetes mellitus confirms this association. Hereafter, a new approach for treating insulin resistance and diabetes may be developed by new therapeutic potentials such as neutralization of Ab by anti-Ab antibodies.
Introduction
The widespread incidence of obesity and aging is instigating an epidemic of type 2 diabetes mellitus (T2D). Hyperglycaemia and hyperinsulinemia are triggered by insulin resistance in peripheral tissues. 1 Protocols for the treatment and prevention of the diabetes mellitus (DM) complications have improved. Consequently, chronic 3 The incidence and prevalence of T2D and AD increase with age. A clear association between T2D and an increased risk of developing AD have been shown by numerous epidemiological studies. [4] [5] [6] Additionally, obesity, hyperinsulinemia, and metabolic syndrome (T2D-related conditions) are risk factors for AD. Increased risk for AD in diabetic patients has been demonstrated by studies specifically assessing the incidence of dementia in people with diabetes mellitus, adjusting for glycemic control, microvascular complications, and comorbidity (e.g. hypertension and stroke), where it is found that an excess risk for AD by 50% to 100% in adults with diabetes was revealed in 8 of 13 population-based studies. The aggregate relative risk of AD for people with diabetes was 1.5 (95% CI), in metaanalysis, with a total of 6184 people with diabetes and 38530 without diabetes. The exact mechanisms with clinical relevance are unclear. Many mechanisms have been suggested, such as insulin resistance and deficiency and impaired insulin receptor and insulin growth factor signalling, to result in advanced glycation end products that may induce cerebrovascular injury and vascular inflammation. 7, 8 C-reactive protein (CRP) is an annular, pentameric protein found in blood plasma whose levels rise in response to inflammation. It is an acute-phase protein of hepatic origin that increases following interleukin-6 secretion by macrophages and T cells. Its physiological role is to bind to lysophosphatidylcholine expressed on the surface of dead or dying cells (and some types of bacteria) in order to activate the complement system via the C1Q complex. 9 D-dimer, a fibrin degradation product (or FDP), is a small protein fragment in the blood which is degraded by fibrinolysis after a blood clot. It contains two D fragments of the fibrin protein joined by a cross-link so it is called D-dimer. 10 The aim of this work is to clarify the bidirectional association between T2D and the pathogenesis of Alzheimer's disease, to evaluate the possibility of utilizing the Ab as biochemical marker of T2D in Alzheimer's patients, and to study the effect of anti-Alzheimer's drugs (piracetam and memantine) on diabetes mellitus.
Patients and methods

Patients
The current study included 120 subjects classified into the following six groups:
Group (I): Twenty healthy control subjects. Group Full patient histories, including age, sex, special habits, occupation, diabetic duration and drug treatments were recorded. The body mass index (BMI) was calculated.
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Written informed consent was recieved from the patients, and this study was approved by the Ethical Committee of a tertiary hospital, KSA.
-Inclusion criteria: Patients suffering from T2D and/or AD aged more than 40 years. -Exclusion criteria: Patients suffering from non-AD dementia, brain infarction, liver diseases, hypertension, heart diseases such as myocardial infarction, malignancy, autoimmune, renal, bone and muscular diseases, acute and chronic inflammatory diseases were excluded.
Sample collection and biochemical analysis
Blood samples were collected after an overnight fast. Fasting plasma glucose (FBG) was determined colorimetrically using a purchased kit, the human diagnostica liquicolor Test (Germany). The HbA1c, glycated haemoglobin, was chromatographically and colorimetrically assessed in whole blood using a kit obtained from BioSystems (Spain 20 
Statistical analysis
The data of the current study were analysed using SPSS (V. 21.0, IBM Corp., USA). For quantitative parametric measures, the data were expressed as the mean AE standard deviation (SD). Whereas, quantitative non-parametric measures were expressed as the median (percentiles range), the Kolmogorov-Smirnov test was used to analyse the distribution of variables. For parametric data, one-way analysis of variance (ANOVA) was used to compare different groups followed by post hoc Bonferroni tests to compare individual groups. For non-parametric data, comparisons between different groups were analysed using the Kruskall-Wallis test followed by comparing individual groups using the Wilcoxon Rank Sum test. Moreover, correlations between different parameters were evaluated using Pearson correlation and ranked Spearman correlation for parametric data and non-parametric data, respectively. Receiver operating characteristic (ROC) curves were plotted in which the value for sensitivity is plotted against 1-specificity. The overall accuracy of a biochemical marker to predict T2D in Alzheimer's patients is defined as the average of the sensitivity and specificity. The association between different parameters adjusted for the effect of other covariates and certain biochemical data was analysed using multiple linear stepwise regression analyses. P values 0.05 were considered significant.
Results
The BMI levels were significantly increased in groups III, IV, V and VI compared to the type 2 diabetic group (II). In addition, diabetic and Alzheimer's patients with symptomatic treatment, treated with memantine and piracetam (groups IV, V and VI), showed a longer duration of diabetes compared to the diabetic group (II), as shown in Table 1 .
The data presented in Table 2 revealed that there were significant increase in the FBG, HbA1c%, and insulin levels in the type 2 diabetic and Alzheimer's patients with symptomatic treatment (group IV) compared to the other groups (II and III). In addition, there were significant decrease in all diabetic markers in the diabetic and Alzheimer's patients treated with anti-Alzheimer's drugs (memantine and piracetam) (groups V and VI) compared to diabetic and Alzheimer's patients with symptomatic treatment (group IV). However, the FBG, HbA1c%, and insulin levels were significantly decreased in diabetic and Alzheimer's patients treated with piracetam compared to diabetic and Alzheimer's patients treated with memantine.
The calculated means AE SD of total and LDL-cholesterol in diabetic and Alzheimer's patients with symptomatic treatment or who were treated with memantine or piracetam (groups IV, V, and VI) showed a significant increase compared to both the type 2 diabetic group (II) and Alzheimer's group (III), as shown in Table 3 . Meanwhile, there was a significant elevation in the triglyceride levels in groups III, IV, V, and VI compared to type 2 diabetic patients. Moreover, the HDL-cholesterol levels in diabetic and Alzheimer's patients with symptomatic treatment or who Table 1 Demographic characteristics of healthy control (group I), diabetic patients (group II), Alzheimer's patients (group III), diabetic and Alzheimer's patients with symptomatic treatment (group IV), diabetic and Alzheimer's patients treated with memantine (group V), and diabetic and Alzheimer's patients treated with piracetam (group VI) Results are expressed as a number (percentage), the mean AE SD and the median (percentiles range). N: Number of subjects; BMI: Body mass index. a Significant difference from healthy control group (I). b
Significant difference from diabetic group (II). P values 0.05 were considered significant.
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were treated with memantine or piracetam (groups IV, V, and VI) showed a significant decrease compared to group III. Table 4 shows that the levels of Ab40 and Ab42 were elevated in diabetic and Alzheimer's patients with symptomatic treatment (group IV) compared to the type 2 diabetic group (II) (by 50.5 and 7.5 fold, respectively) and Alzheimer's group (III) (by 25.4 and 2.8 fold, respectively). In group III, the Ab40 and Ab42 levels were increased by 2 and 2.7 fold, respectively, compared to the type 2 diabetic group (II). In addition, Ab40 and Ab42 were elevated in the diabetic and Alzheimer's patients treated with memantine or piracetam (groups V and VI) compared to groups II and III. The CRP levels showed a significant increase in diabetic and Alzheimer's patients with symptomatic treatment or who were treated with memantine or piracetam (groups IV, V and VI) compared to both groups II and III. Additionally, there were significant increase in the levels of total CK and LDH in groups IV, V and VI compared to the type 2 diabetic group (I). Diabetic and Alzheimer's patients with symptomatic treatment or who were treated with memantine or piracetam (groups IV, V and VI) showed a significant increase in the D-dimer level compared to both groups II and III. On the other hand, the median (percentile range) of magnesium in diabetic and Alzheimer's patients with symptomatic treatment or who were treated with memantine or piracetam (groups IV, V and VI) was decreased compared to groups II and III.
Positive correlations were detected between insulin and Ab40, Ab42, CRP, total CK and D-dimer. Meanwhile, the HbA1c and lipid profile (total cholesterol, triglycerides and LDL-cholesterol were positively correlated with Ab40, Ab42, CRP, and CK. The HbA1c was positively significantly correlated with total LDH. Additionally, positive significant correlations were detected between both total and LDL-cholesterol and D-dimer. However, the correlations between magnesium and HbA1c, insulin, total cholesterol and LDL-cholesterol were negative but significant in groups II, III, IV, V, and VI as shown in Table 5 and Figure 1 .
Positive correlations of Ab40 and Ab42 with CRP, total CK, and D-dimer were recorded in groups II, III, IV, V, and VI, as presented in Table 6 and Figure 2 . However, there were negative correlations between magnesium and Ab40 and Ab42. Table 3 Lipid profile tests of healthy control (group I), diabetic patients (group II), Alzheimer's patients (group III), diabetic and Alzheimer's patients with symptomatic treatment (group IV), diabetic and Alzheimer's patients treated with memantine (group V), and diabetic and Alzheimer's patients treated with piracetam (group VI) Furthermore, by using Ab40 as the dependent variable and other investigated parameters as independent variables in multiple linear stepwise regression analysis, only the DM duration (b ¼ 0.14, P < 0.01), HDL-cholesterol (b ¼ À0.15, P < 0.01) and Ab42 (b ¼ 0.83, P < 0.01) remained correlated with Ab40.
In multiple linear stepwise regression analysis using Ab42 as the dependent variable and the other investigated parameters as independent variables, only the DM duration (b ¼ 0.11, P < 0.05), HDL-cholesterol (b ¼ À0.17, P < 0.01), and Ab40 (b ¼ 1.11, P < 0.01) remained correlated with Ab42.
Additionally, by using CRP as the dependent variable and other investigated parameters as independent variables in multiple linear stepwise regression analysis, only Ab40 (b ¼ 1.1, P < 0.01) and total CK (b ¼ 0.46, P < 0.01) remained correlated with CRP.
Moreover, by using HbA1c as the dependent variable and other investigated parameters as independent variables in multiple linear stepwise regression analysis, only HDLcholesterol (b ¼ À 0.65, P < 0.01) and CRP (b ¼ 0.42, P < 0.01) remained associated with HbA1c.
Meanwhile, by using insulin as the dependent variable and other investigated parameters as independent variables in multiple linear stepwise regression analysis, only the DM duration (b ¼ 0.32, P < 0.01) and Ab40 (b ¼ 0.62, P < 0.01) remained correlated with insulin. Eventually, by using total cholesterol and LDL-cholesterol as dependent variables and other investigated parameters as independent variables in multiple linear stepwise regression analysis, Table 5 Correlations between diabetic markers, lipid profile and different investigated parameters in diabetic, Alzheimer's, diabetic and Alzheimer's patients with symptomatic treatment groups, diabetic and Alzheimer's patients treated with memantine, and diabetic and Alzheimer's patients treated with piracetam (II, III, IV, V and VI), n ¼ 100
Parameters
Diabetic markers and lipid profile Ab40 (pg/mL) As illustrated in Figure 3 , the receiver operator characteristic (ROC) analyses of the biochemical markers (Ab40, Ab42, CRP, D-dimer, total LDH, and CK); the areas under the curve (AUC) were 0.946, 0.921, 0.889, 0.734, 0.754, and 0.900, respectively and thus Ab40 is the most reliable predictor of T2D in Alzheimer's patients.
Discussion
The present research was planned to investigate the bidirectional association between T2D and AD pathogenesis.
Recent epidemiological studies have demonstrated that individuals with T2D are two to four times more expected to develop AD. 21 There were significant increase in the BMI levels in groups III, IV, V, and VI compared to the type 2 diabetic group (II). In obesity, brain health is affected by altered adipokine signaling. Changes in adipokine function may mitigate the pathogenesis of AD were suggested by both population and experimental studies. 22 Higher BMI for participants with AD compared with non-AD participants with similar age was reported by a retrospective study with 18 year follow-up on women with dementia. The AD risk increased by 36% for every 1.0 increase in BMI at age 70 years, further highlighting the effect of overall adiposity on cognitive function at any given age. 23 The present study revealed that FBG and HbA 1c % levels were increased in diabetic and Alzheimer's patients treated symptomatically (group IV) compared to the diabetic group (II), and this was confirmed by the positive and significant correlations between HbA 1c % and Ab40, Ab42, total CK and LDH. Volpe et al. 24 stated that poor glycaemic control (HbA 1c > 6.5%) was positively correlated with increased plasma levels of tumour necrosis factor alpha and vascular endothelial growth factor in T2D patients, reflecting the activation of innate immune cells and also high levels of malondialdehyde (MDA), indicating the presence of oxidative stress in T2D patients compared with healthy control individuals. Oxidative stress is a risk factor for development of AD. The damage to proteins and nucleic acids is mediated by excess of reactive Table 6 Correlations between Ab40, Ab42, and different investigated parameters in diabetic, Alzheimer's, diabetic and Alzheimer's patients with symptomatic treatment groups, diabetic and Alzheimer's patients treated with memantine, and diabetic and Alzheimer's patients treated with piracetam (II, III IV, V, and VI), n ¼ 100
0.87** 0.23 À0.66** Ab42 (pg\mL) 0.84** 0.2 À0.63**
Results are expressed as correlation coefficients (r). Ab40: amyloid b40; Ab42: amyloid b42; CRP: C-reactive protein; total CK: total creatine kinase; total LDH: total lactate dehydrogenase. **P 0.01. oxygen/reactive nitrogen species, causing direct and deleterious consequences in AD. Additionally, oxidative stress induces advanced glycation end products by lipid peroxidation and glycoxidation, which are common in AD and serve as markers of disease progression. 25 This was in agreement with the work of Ramirez et al., 26 who reported that higher levels of HbA 1c % were correlated with increased risk of AD in an elderly population.
By measuring plasma lipid profiles, HbA1c % was positively significantly correlated with total cholesterol (r ¼ 0.64, P < 0.01). Similarly, Regmi et al. 27 revealed an increase in the prevalence of hypercholesterolemia, hypertriglyceridemia, and high LDL-cholesterol levels in diabetic patients.
Several studies showed that in diabetic patients, insulin affects the liver production of apolipoprotein, regulates the lipoprotein lipase activity and cholesterol ester transport protein, causing dyslipidemia. 28 Additionally, insulin resistance decreases the hepatic lipase activity and several processes in the biologically active lipoprotein lipase synthesis. In addition, hyperglycaemia elevates the cholesterol esters synthesis from HDL-cholesterol to VLDL-cholesterol particles; hence, denser LDL particles acquire a large proportion of these HDL-esters, more decreasing the level of HDL-cholesterol. Additionally, poor insulinization causes elevated lipolysis in adipocytes, leading to increased transport of fatty acid to the liver, and thus an increase in VLDL-cholesterol. 29 Furthermore, the present results showed that there was a significant elevation in total cholesterol, triglycerides and LDL-cholesterol in group IV compared to groups II and III. There were significant positive correlations between total cholesterol and LDL-cholesterol and Ab40 and Ab42. Approximately 30% of the total body's cholesterol is in the brain, the most cholesterol-rich organ. Cholesterol is an crucial constituent of cell membranes in cholesterol, which plays an essential role in the progression and maintenance of plasticity and function of nerves. Neuronal plasticity is abnormal and neuronal function in turn is compromised in AD. A [beta] is produced by enzymatic cleavage of amyloid precursor protein (APP).
[Gamma]-secretase cleaves APP in the core of the plasma membrane, so changes in the membrane lipid environment of [gamma]-secretase alter a [beta] production and hence AD pathogenesis. It has been supposed that an increase in membrane cholesterol may indirectly stimulate formation of neurofibrillary tangles. Other changes in AD that produce an oxidative imbalance have been attributed to toxicity related to amyloid-and/or metal metabolism in the brain and peripheral tissues. There is evidence that high concentrations of oxidized derivatives of cholesterol (oxysterols) can stimulate neuronal apoptosis and exocytosis. 30 The present results also demonstrated a significant increase in insulin levels in the diabetic and Alzheimer's group (IV) in comparison with the diabetic patients (group II). Also, there was a significant increase in the levels of Ab40 and Ab42 in diabetic and Alzheimer's patients with symptomatic treatment (group IV) compared to Alzheimer's patients (group III). These results are in agreement with the significant positive correlations between insulin and Ab40 and Ab42. The dysfunction in insulin production and insulin resistance could lead to a decline in acetylcholine levels, which may alter cognition and memory. Interestingly, insulin modifies amyloid beta levels by elevation its secretion or by cessation insulin-degrading enzyme (IDE). Because of the strong Ab-degrading ability of IDE, a decrease in IDE activity in the brain can be a direct trigger of Ab deposition to develop AD. 32 Meanwhile, the current study coincides with the study of Zhao et al. 33 which provided evidence that the reduction of IDE caused by altering the action of insulin in the brain might accelerate the onset of AD. By contrast, IDE has a role in maintaining insulin sensitivity in the body. 32 It is very interesting to discover the mechanisms whereby AD affects the diabetic phenotype. Several hypotheses can be suggested. First, there is an alteration in the central control of metabolism of peripheral glucose in AD. Second, plasma amyloid beta may facilitate peripheral insulin resistance. Third, Ab accumulates in the pancreas. 34 Zhang et al. 35 found that APP/presenilin 1 (PS1) transgenic AD mice with elevated plasma Ab 40/42 levels have impaired hepatic insulin signalling and glucose/insulin tolerance and activation of the JAK2/STAT3/SOCS1 pathway. The JAK/STAT/SOCS pathway was recognized as downstream of inflammatory cytokines, by which inflammation elevates insulin resistance in the peripheral system. 36 Zhang et al. 37 extended this line of study by analysing the role of plasma Ab in insulin resistance. Additionally, FBG, HbA1c%, and insulin levels were decreased in diabetic and Alzheimer's patients who received anti-Alzheimer's drugs (particularly piracetam) compared to diabetic and Alzheimer's patients who received symptomatic treatment (group IV). This result proved the ameliorating effect of anti-Alzheimer's drugs on diabetes mellitus. All of the mentioned evidence confirms, without doubt, the bidirectional association between diabetes and AD pathogenesis.
Moreover there was a significant increase in CRP levels in diabetic and Alzheimer's patients who received symptomatic treatment (group IV) compared to group II and a positive significant correlation between HbA1c% and CRP. T2D is an inflammatory atherothrombotic condition. The inflammatory and metabolic factors are correlated with diabetes, such as hyperglycemia, modified lipoproteins, adipokines and free fatty acids, may cause CRP production, which participates in the systemic response to inflammation. 38 Moreover, the present work showed significant positive correlations between CRP and Ab40 and Ab42, agree with the work of Yarchoan et al., 39 which provided evidence that chronic inflammatory diseases, such as AD, are associated with increases in plasma CRP.
Higher CRP levels were related to elevated levels of cerebral myoinositol (mI)/creatine (Cr), a biomarker of glial proliferation, due to increased blood brain barrier permeability, causing neurochemical changes linked to increased brain water diffusion and development of cognitive impairment conditions, such as AD. In addition, CRP is involved in autotoxic cascades causing decreased endothelial integrity, which may negatively impact cognition and cerebrovascular autoregulation. 40 On the other hand, CRP is found to be associated with tangle and plaque pathology in the AD brain. 41 C-reactive protein may also contribute to atherosclerotic processes and can increase the expression of adhesion molecules (intercellular and vascular cell adhesion molecules) in vascular endothelial cells in the human brain, explaining the positive significant correlation between CRP and D-dimer. Atherosclerosis of cerebral vessels may induce hypoperfusion and hypoxia, enhancing the production of Ab peptide, which may promote the f atherosclerotic lesions formation through endothelial dysfunction and vascular oxidative stress leading to additional vascular damage. 42 Furthermore, the current study found that there was a significant elevation in the plasma levels of D-dimer in group (IV) in comparison with group (II) and a positive significant correlation between HbA1c and D-dimer. Diabetes may be associated with enhanced lesion instability and atherosclerotic plaque rupture with superimposed thrombus formation. These changes are principally mediated by the insulin resistance, dysglycaemia and an elevated inflammatory state that alters the function of platelet, clot structure, and coagulation factors. 43 The results of the present study showed a positive significant association between D-dimer and Ab40 and Ab42. Meanwhile, the present results are in agreement with the work of Carcaillon et al., 44 who stated that elevated D-dimer levels were associated with vascular dementia such as AD.
In the present study, it was proved that the levels of magnesium were diminshed in diabetic and Alzheimer's patients who recieved symptomatic treatment (group IV) compared to the diabetic group (II), and was confirmed by a negative significant correlation between HbA1c and magnesium. An increased prevalence of Mg deficit has been identified in type 2 diabetic patients, in particular with those having poorly controlled glycaemic profiles and a longer duration of the disease. 45 The urinary Mg excretion and fasting blood glucose displayed an inverse relation with serum Mg levels. Increased glucose and insulin levels in the blood may increase urinary Mg excretion. Thus, hyperglycaemia decreases Mg tubular reabsorption. 46 There were significant negative correlations between magnesium and Ab40 and Ab42. Magnesium plays a crucial role in many critical cellular processes, such as cellular respiration, oxidative phosphorylation, glycolysis and synthesis of protein. Decreased magnesium in the hippocampus is an important pathogenic factor in AD. 47 
Conclusion
We conclude that Ab40, Ab42, insulin, HbA1c, lipid profile disturbance, CRP, D-dimer, and magnesium have an important role in the bidirectional association between T2D and AD pathogenesis, which is confirmed by the ameliorating effect of piracetam and memantine drugs on diabetes mellitus. In addition, amyloid beta (especially Ab40) can be utilized as biochemical marker of T2D in Alzheimer's patients.
